Russia's Avifavir coronavirus drug registered in Indonesia - RDIF
MOSCOW. March 24 (Interfax) - Indonesia has registered Russia's Avifavir coronavirus drug, the Russian Direct Investment Fund (RDIF) said in a statement on Wednesday.
"The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) and ChemRar Group announce that Russian anti-COVID Favipiravir-based drug Avifavir has been registered by the National Agency of Drug and Food Control of Indonesia," RDIF said.
Avifavir was registered in Indonesia under an accelerated procedure based on data obtained during an extended phase II-III clinical trial, which took place in Russia, RDIF said. According to the developer, the efficacy of the drug was above 80% and the median elimination of the virus took four days compared to nine days with standard therapy.
Avifavir is supplied to all constituent territories of Russia and 15 other countries.